The ASSESSMENT of SERPINB3 Expression, PAR2, and SCCA-PD Polymorphism in Patients with Acute Respiratory Distress Syndrome

What this Trial Is About

Researchers are studying Acute Respiratory Distress Syndrome (ARDS), a severe lung condition that causes respiratory failure, inflammation, and tissue damage, often leading to high mortality. The study focuses on understanding the roles of SERPINB3, PAR2, and the SCCA-PD polymorphism in ARDS patients. These molecules are believed to contribute to lung injury and fibrosis, but their involvement in ARDS patients has not been previously confirmed. This research aims to identify patient subgroups at higher risk and support the development of targeted treatments. The study will observe two groups: patients with ARDS requiring invasive mechanical ventilation and control patients in intensive care needing ventilation for reasons other than respiratory failure. Data collected include clinical, ventilatory, and biomolecular information. Participants will have high-resolution chest CT scans within 72 hours of ARDS diagnosis and again around 21 days later or at hospital discharge. Blood and bronchoalveolar lavage samples will be collected within 72 hours and, if possible, at 21 days to analyze SERPINB3, PAR2, and SCCA-PD expression and their association with lung fibrosis. During the study, researchers will monitor the progression of lung fibrosis using imaging and biomarker analysis. They will assess SERPINB3 and SCCA-PD levels shortly after diagnosis and evaluate fibrosis and mortality risk models at later time points. Data collection will continue until hospital discharge. The study uses leftover clinical samples for research and tracks outcomes including 60-day mortality. Overall participation duration varies with hospital stay and follow-up timing.

SerpinB3 Expression, PAR2 and SCCA-PD Polymorphism in Acute Respiratory Distress Syndrome